Thursday, 23 Jan 2020

You are here

Altering the Microbiome May Benefit Lupus Patients

Previous research has suggested a potential role for gut dysbiosis and alterations Th17 and regulatory T (Treg), along with IL-17, IL-22, and IL-23, in the pathogenesis of SLE. 

Lopez and colleagues from Spain have studied the gut microbiome of lupus patients and reported that lupus microbiota promoted lymphocyte activation and Th17 differentiation from naïve CD4+ lymphocytes moreso than that seen with healthy control-microbiota. 

The addition of Bifidobacterium bifidum, Ruminococcus obeum and Blautia coccoides strains to the lupus microbiota abrogated these effects.

They also found that the fecal microbiota of normal controls exhibited a negative correlation between IL-17+ populations and Firmicutes species, but in SLE this phylum correlated directly with serum levels of IFNγ. Synergistetes, positively correlated with the Firmicutes/Bacteroidetes ratio in healthy controls, but tended to be reduced in lupus patients when anti-dsDNA titers were increased and also negatively correlation with IL-6 serum levels and IgM anti-phosphorylcholine antibodies.

These preliminary findings suggest a potential role for microbiome manipulation as a means of disease control in lupus patients.  More research is called for.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I looked these microbiotia up and did not find either of the Ruminococcus species available.

More Like This

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.